RT Journal Article
SR Electronic
T1 Modelling upper respiratory viral load dynamics of SARS-CoV-2
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.05.01.21256182
DO 10.1101/2021.05.01.21256182
A1 Challenger, Joseph D.
A1 Foo, Cher Y.
A1 Wu, Yue
A1 Yan, Ada W. C.
A1 Marjaneh, Mahdi Moradi
A1 Liew, Felicity
A1 Thwaites, Ryan S.
A1 Okell, Lucy C.
A1 Cunnington, Aubrey J.
YR 2021
UL http://medrxiv.org/content/early/2021/07/06/2021.05.01.21256182.abstract
AB Relationships between viral load, severity of illness, and transmissibility of virus, are fundamental to understanding pathogenesis and devising better therapeutic and prevention strategies for COVID-19. Here we present within-host modelling of viral load dynamics observed in the upper respiratory tract (URT), drawing upon 2172 serial measurements from 605 subjects, collected from 17 different studies. We developed a mechanistic model to describe viral load dynamics and host response, and contrast this with simpler mixed-effects regression analysis of peak viral load and its subsequent decline. We observed wide variation in URT viral load between individuals, over 5 orders of magnitude, at any given point in time since symptom onset. This variation was not explained by age, sex, or severity of illness, and these variables were not associated with the modelled early or late phases of immune-mediated control of viral load. We explored the application of the mechanistic model to identify measured immune responses associated with control of viral load. Neutralizing antibody correlated strongly with modelled immune-mediated control of viral load amongst subjects who produced neutralizing antibody. Our models can be used to identify host and viral factors which control URT viral load dynamics, informing future treatment and transmission blocking interventions.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by a research grant (MR/V027409/1) from UKRI (MRC) and DHSC (NIHR). Infrastructure support was provided by the NIHR Imperial Biomedical Research Centre. JDC and LCO acknowledge funding from the MRC Centre for Global Infectious Disease Analysis (reference MR/R015600/1), jointly funded by the UK Medical Research Council (MRC) and the UK Foreign, Commonwealth & Development Office (FCDO), under the MRC/FCDO Concordat agreement and is also part of the EDCTP2 programme supported by the European Union. AWCY was funded by a Wellcome Trust Investigator Award to Becca Asquith (103865Z/14/Z).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics statement: This study conducted secondary analysis of data from published studies. All studies included were either (i) approved by an institutional ethics review committee and obtained informed consent from all participants; or (ii) were exempted from this requirement because they involved identification, control, or prevention of disease in response to an immediate public health threat, and had been determined not to be public health research. Further ethical approval was not required for the present study which used only anonymised non-identifiable information from these studies.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAt present, we refer the reader back to the original studies (summarised in Table 1) to access or request the viral load data.